Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACETNASDAQ:JANXNASDAQ:MRSNNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.67-0.1%$0.67$0.45▼$1.70$55.33M1.67711,810 shs276,514 shsJANXJanux Therapeutics$22.72-0.8%$26.77$22.48▼$71.71$1.34B2.96870,163 shs660,534 shsMRSNMersana Therapeutics$0.36+1.7%$0.36$0.26▼$2.83$44.38M0.832.64 million shs808,745 shsSIGASiga Technologies$6.42+1.9%$6.01$4.95▼$12.83$458.65M0.93727,268 shs317,037 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio0.00%-14.22%-10.73%-12.67%-50.07%JANXJanux Therapeutics0.00%-11.11%-10.55%-24.11%-43.76%MRSNMersana Therapeutics0.00%-1.93%-8.69%-16.29%-82.54%SIGASiga Technologies0.00%-0.31%+3.55%+14.44%+1.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio2.4736 of 5 stars3.32.00.00.03.31.70.6JANXJanux Therapeutics2.0104 of 5 stars3.52.00.00.01.52.50.0MRSNMersana Therapeutics3.8531 of 5 stars3.54.00.04.10.02.50.0SIGASiga Technologies1.9876 of 5 stars0.03.00.00.01.50.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$7.501,021.08% UpsideJANXJanux Therapeutics 3.09Buy$95.25319.23% UpsideMRSNMersana Therapeutics 3.00Buy$5.201,360.26% UpsideSIGASiga Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACET, SIGA, JANX, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.003/21/2025ACETAdicet BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M2.21N/AN/A$2.26 per share0.30JANXJanux Therapeutics$10.59M126.94N/AN/A$19.49 per share1.17MRSNMersana Therapeutics$40.50M1.10N/AN/A($0.08) per share-4.45SIGASiga Technologies$138.72M3.31$0.84 per share7.67$3.02 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$117.12M-$1.30N/AN/AN/AN/A-59.05%-50.66%8/12/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/A-463.91%-9.29%-8.89%8/6/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)SIGASiga Technologies$59.21M$0.679.585.14N/A40.30%25.21%22.05%7/30/2025 (Estimated)Latest ACET, SIGA, JANX, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/8/2025Q1 2025SIGASiga TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million5/6/2025Q1 2025ACETAdicet Bio-$0.34-$0.31+$0.03-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet BioN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest ACET, SIGA, JANX, and MRSN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASiga Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A9.349.34JANXJanux TherapeuticsN/A58.4758.47MRSNMersana Therapeutics13.351.831.83SIGASiga TechnologiesN/A8.406.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%JANXJanux Therapeutics75.39%MRSNMersana Therapeutics93.92%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio7.80%JANXJanux Therapeutics8.10%MRSNMersana Therapeutics13.00%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9082.71 million76.26 millionOptionableJANXJanux Therapeutics3059.17 million54.38 millionOptionableMRSNMersana Therapeutics150124.63 million108.43 millionOptionableSIGASiga Technologies4071.44 million70.05 millionOptionableACET, SIGA, JANX, and MRSN HeadlinesRecent News About These CompaniesUndiscovered Gems In US Market Including SIGA Technologies And 2 Other Small CapsJune 17 at 4:43 AM | finance.yahoo.comBank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)June 16, 2025 | marketbeat.comWhy Siga Technologies Inc. (SIGA) Dipped More Than Broader Market TodayJune 13, 2025 | zacks.comSIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.June 13, 2025 | marketbeat.comInvestors Purchase Large Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12, 2025 | americanbankingnews.comTraders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12, 2025 | marketbeat.comSIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in MayJune 4, 2025 | marketbeat.comTraders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 87,853 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)May 21, 2025 | marketbeat.comWe Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster EarningsMay 16, 2025 | finance.yahoo.comUndiscovered Gems in the US Market for May 2025May 16, 2025 | finance.yahoo.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comHere's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market TodayApril 25, 2025 | zacks.comSiga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to KnowApril 23, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACET, SIGA, JANX, and MRSN Company DescriptionsAdicet Bio NASDAQ:ACET$0.67 0.00 (-0.15%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.67 +0.00 (+0.60%) As of 06/18/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Janux Therapeutics NASDAQ:JANX$22.72 -0.19 (-0.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$22.75 +0.03 (+0.13%) As of 06/18/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Mersana Therapeutics NASDAQ:MRSN$0.36 +0.01 (+1.74%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.81%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Siga Technologies NASDAQ:SIGA$6.42 +0.12 (+1.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$6.32 -0.10 (-1.50%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
